Difference between revisions of "Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma"

From MicrobeWiki, the student-edited microbiology resource
Jump to: navigation, search
Line 47: Line 47:
 
1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <i> Journal of clinical oncology, 33(25), </i> 2780-2788. <https://s3.amazonaws.com/academia.edu.documents/41260637/Talimogene_Laherparepvec_Improves_Durabl20160115-22239-yubl2z.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1522701871&Signature=rttGQ7Dqvp0CPvJGeXHU5jkWlU4%3D&response-content-disposition=inline%3B%20filename%3DTalimogene_Laherparepvec_Improves_Durabl.pdf>.
 
1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <i> Journal of clinical oncology, 33(25), </i> 2780-2788. <https://s3.amazonaws.com/academia.edu.documents/41260637/Talimogene_Laherparepvec_Improves_Durabl20160115-22239-yubl2z.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1522701871&Signature=rttGQ7Dqvp0CPvJGeXHU5jkWlU4%3D&response-content-disposition=inline%3B%20filename%3DTalimogene_Laherparepvec_Improves_Durabl.pdf>.
  
2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy.<i> Oncoimmuneology, 5(1), </i> e1115641 (3 pages)>.
+
2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy.<i> Oncoimmuneology, 5(1), </i> e1115641 (3 pages). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760283/>.
  
3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. <i> Gene Therapy, 10(4), </i> 292>.
+
3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. <i> Gene Therapy, 10(4), </i> 292>. <https://www.nature.com/articles/3301885>.
  
  
 
<br><br>Authored for BIOL 238 Microbiology, taught by [mailto:slonczewski@kenyon.edu Joan Slonczewski], 2018, [http://www.kenyon.edu/index.xml Kenyon College].
 
<br><br>Authored for BIOL 238 Microbiology, taught by [mailto:slonczewski@kenyon.edu Joan Slonczewski], 2018, [http://www.kenyon.edu/index.xml Kenyon College].

Revision as of 19:31, 15 April 2018

This is a curated page. Report corrections to Microbewiki.

Classification

Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm

Overview of Talimogene Laherparepvev (T-VEC)

Figure 1: Transmission Electron Micrograph of a Herpes Simple Virus Particle by Jay C. Brown of the University of Virginia. [http://darwin.bio.uci.edu/~faculty/wagner/hsv2f.html.


By Alex Fazioli

Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].



Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+

Section 2

Include some current research, with at least one figure showing data.

Section 3

Include some current research, with at least one figure showing data.

Section 4

Conclusion

References


1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788. <https://s3.amazonaws.com/academia.edu.documents/41260637/Talimogene_Laherparepvec_Improves_Durabl20160115-22239-yubl2z.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1522701871&Signature=rttGQ7Dqvp0CPvJGeXHU5jkWlU4%3D&response-content-disposition=inline%3B%20filename%3DTalimogene_Laherparepvec_Improves_Durabl.pdf>.

2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy. Oncoimmuneology, 5(1), e1115641 (3 pages). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760283/>.

3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292>. <https://www.nature.com/articles/3301885>.




Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.